

What: Operations Committee Meeting
Date & Time: October 23, 2025; 12:30-1:30 p.m. PT

Location: Individual Zoom Links

Notice: The meeting is recorded for the benefit of the minute-taker, the recording will be deleted after the minute approval.

#### Agenda

Approx. Time	Time	Page	*	Topic/[Anticipated Action]	Presented by:
12:30-12:35 p.m.	5 min			Introductions & Agenda Review     a. Notice of Recording	J. Zell
	- ·			<u> </u>	1.77.11
12:35-12:40 p.m.	5 min	Pg. 3-4	*	Action Items     a. Vote to Approve Operations Committee	J. Zell
				Minutes, April 24, 2025	
12:40-1:20	40			3. Operations Updates	
p.m.	min	Pg. 7-13	*	a. Vaccine Assessment Loss (VAL)	J. Zell /
				i. Payer Compliance	P. Miller
				ii. Provider Compliance/WCAAP Collaboration	K. Walker
				iii. Supply Chain/Inventory	J. Zell/
				Management	P. Miller
				iv. Discussion	
		Pg. 14-15	*	b. Future of Assessment Grid	J. Zell
				c. Survey of Other Matters	Any
1:20-1:25 p.m.	5 min			4. Public Comment (if time permits)	Any
1:25-1:30 p.m.	5 min			6. Closing	J. Zell

\*Indicates agenda item attached Red text indicates an action item



#### October 23, 2025

#### **WVA Meeting of the Operations Committee**

#### **Proposed Form of Votes**

The following are suggested forms of votes only. They are intended to be an aid to facilitate work by individual directors and committee members.

#### **Items under Agenda Section 2:**

VOTED: To approve April 24, 2025 committee meeting minutes.

[To approve April 24, 2025 committee meeting minutes with the changes suggested at the meeting.]



1 2 3		Washington V Operations C April 24, 2025;	ommi	ittee Meeting		
4		11p1 1 2 1, 2023,	12.00	, 1.00 p.m. 1 1		
5	I.	Attendance. Participating in all or part of	the m	neeting by telephone were the following individuals:		
6	3.6 1		20	WW.7.4		
7	Members 1	TT 1. 1		WVA		
8	Kara Manle		21	Julia Zell, Esq., Executive Director, Chair		
9		subramanian, Aetna	22	Cheri Cagle, Stakeholder Liaison		
10		er, Cambia/Regence	23	Kerrie Walker, Deputy Manager		
11	Tracey Car	•	24			
12	Veronica G		25	Helms & Company, Inc.		
13		berg, Premera	26	Patrick Miller, MPH, Administrative Director		
14	Erika Cliett		27	Ashley Ithal, MPH, Project Support Leader		
15	Cheryl Rain	righ, Regence	28	Terri Perkins, Senior Client Support Specialist		
16	Brittany Ar	neden, Premera	29	Leslie Walker, CPA, Mason+Rich, PA		
17	Liz Story, C	Cigna	30			
18	0.1					
19						
32	II.	Summary of Actions Taken and/or Reco	mme	nded		
33						
34		ken (votes adopted)				
35	i. To	approve October 24, 2024 meeting minutes.				
36						
37	III.	Minutes				
38						
39		nd Introductions				
40				ed a notice of recording for the purposes of the meeting		
41	minutes. Sh	e stated the recording will be deleted once the	e mee	eting minutes are approved.		
42	G . G					
43	<u>Consent Calendar</u> Ms. Zell asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously					
44	Ms. Zell asl	ked for a motion to approve the minutes. Upo	on mo	ation duly made and seconded, it was unanimously		
45		VOTED: To our ways October 24	202	1		
46		VOTED: To approve October 24	, 2024	4 meeting minutes.		
47 48	IV.	Operational Updates				
49	IV.	Operational Opulates				
50	Accessment	Grid				
51	Assessment Grid Mr. Miller presented an overview of the proposed FY2026 WVA Vaccine Assessment Grid (Grid). The weighted					
52	vaccine Grid amounts are increasing by 24%. The increase allows the WVA to rebuild reserves in order to stabilize					
53	future vaccine assessments as new routine immunizations are introduced while also mitigating the costs for respiratory					
54	season immunization losses and overall vaccine inflation increases.					
55	Season min	asinzation losses and overall vaccine initiation		(Cases)		
56	After discu	ssion, Ms. Zell asked for a motion to finaliz	e the	FY2026 assessment grid. Upon motion duly made and		
57	seconded, it was unanimously					
58	,	•				
59		<b>VOTED:</b> To finalize the 2025-26	WVA	A Vaccine Assessment Grid.		
60						
61	Mr. Miller	will finalize and post the Grid to the WVA w	ebsite	e by May 1st. Email and physical mail will be sent in		
62	May to both payers and providers.					
63						
64	Vaccine As	sessment Loss (VAL)				
65	Mr. Miller discussed Vaccine Assessment Loss (VAL) which he defined as the gap between funded vaccines and					

collected assessments. He explained multiple factors which contribute to VAL before identifying known gaps and

66

potential solutions. The WVA will expend additional resources this calendar year to work with payers and providers to better understand the causes and reduce VAL. Further discussion addressed the need for improved data sharing between the WVA and the Department of Health, as well as provider inventory management and the possibility of creating a VAL reduction taskforce.

V. Public Comment - No public comments.

VI. Closing

Ms. Zell concluded the meeting at 1:24 p.m.





# **Operations Committee Meeting**

October 23, 2025



# 3. Operations Update



### 3.a. VAL Action Plan Goals and Expected Outcomes

#### Vaccine Assessment Loss (VAL): uncollected monies for WVA funded vaccines

# GOAL: Payer DBA Compliance

- » Payer DBA Accuracy
- » Payer Equity

# GOAL: Provider DBA Compliance

- » Provider DBA Accuracy
- » Provider Education
- » Provider Onboarding Consistency

# GOAL: Supply Chain Efficiency

- » Efficient Inventory Levels
- » Reduce Expired Doses
- » Waste & Return Accountability
- » Provider Technical Assistance



### 3.a. Vaccine Assessment Loss: KPIs (as of 10.15.2025)

### Vaccine Assessment Loss (VAL): uncollected monies for WVA funded vaccines

## **GOAL**: Payer DBA Compliance MONTHLY MEASURES

- » Reduce Percentage of Unrecovered DBAs
- » #/\$ of DBA Audits In Progress
- » #/\$ of DBA Audits Closed

## **GOAL**: Provider DBA Compliance MONTHLY MEASURES

- » # of Providers Clinics Verified for DBA Compliance: by Phase
- » # of Provider DBA Errors Identified

# GOAL: Supply Chain Efficiency MONTHLY MEASURES

- **»** % of Providers Ordering Monthly
- » % Waste & Returns
- » % IIS Administered Doses to Shipments (Vaccine Uptake)



## 3.a. VAL Plan Progress (as of 10.15.2025)

	Payer DBA Compliance	Provider DBA Compliance	Supply Chain Efficiency	Information Management	Other
Completed	<ul> <li>✓ Payer specific compliance audits (15)</li> <li>✓ Payer webinar training</li> <li>• New, Q4 Payer DBA</li> </ul>	<ul> <li>✓ Revised provider onboarding process</li> <li>✓ Order shutoff for non-compliance</li> <li>• New, Q4 Provider DBA</li> </ul>	<ul> <li>✓ 25% COVID-19 reduction</li> <li>✓ COVID-19 ordering caps</li> <li>✓ RSV ordering caps</li> <li>• Expiring RSV dose</li> </ul>	<ul> <li>✓ MediStreams implementation</li> <li>✓ Database model development</li> <li>✓ Past six-month vaccine data rec'd</li> <li>Data Sharing Agreement</li> </ul>	<ul> <li>✓ WVA set \$3M liquidity floor</li> <li>✓ Bi-monthly DOH transfers</li> <li>✓ Up to \$8M can go negative with DOH</li> <li>Fund source split</li> </ul>
In Progress	compliance reporting (quarterly  On-going payer audits	compliance reporting	<ul> <li>management/Transfers</li> <li>WCAAP partnership</li> <li>COVID-19 rollout</li> <li>Enflonsia RSV rollout</li> </ul>	renewal application  • 4-year Retroactive data requested	analysis • KPIs by workstream
Planned			<ul> <li>WCAAP clinical guidance for multiple RSV products</li> <li>WCAAP Coaching</li> <li>Restitution Policy</li> </ul>	<ul> <li>Data linkage by Lot Number</li> <li>FY 2027 Assessment modeling updates</li> <li>Data quality efforts</li> </ul>	Page Number 9

### 3.a.i. 2025 Payer DBA Compliance Reviews

### **TIMELINE**

- » May 2025: Payer Bulletin Statutory Notice of New Assessment Grid
- » May 2025: Respiratory DBA Compliance Analysis for 16 Payers; Recoveries of \$500K
- » Sep 2025: DBA Compliance Analysis for 15 Payers; Recoveries Expected of \$1.5M
- » Q4 2025: Change to Quarterly Reports

### **ISSUES**

- » Provider DBA Submission Education Opportunities
- » Full Grid Amount Not Paid to WVA
- » Incorrect Full and Partial Denials Due To:
- **»** Patient Cost-Sharing (e.g., deductibles, co-pays, coinsurance, benefit maximums, etc.)
  - » Out-of-Network Restrictions
  - » Timely Filing Limits
  - » Referral or Pre-Certification Requirements
  - » Experimental Codes
  - » Home/Host Plan Processing Issues



## 3.a.i. New Payer Compliance Reporting Process

- 1 WVA Issues Quarterly (Receipt Date) Payer Compliance Reports
  - » Requested 2 Week Response
  - » Identifies Specific CARCs/RARCs and WVA's Requested Action(s)
- Payer Responses to Include:
  - » Display/Call Out of Providers Appearing to Incorrectly Submit DBAs
  - » Notification of Reprocessed Volume and Fiscal Impact
- 3 Payer Notification to WVA of Reprocessed DBAs:
  - » Provide WVA With Detailed File Post-Reprocessing
- 4 Payer Settlement Report Option Available

\*\*\* WVA WASHINGTON VACCINE ASSOCIATION


### 3.a.ii. New Provider Compliance Report: DBA Submission Errors

- » New, Monthly Provider Compliance Report in Q4 2025 (Based Upon DBA 835 Data)
- » Evaluated DBA Errors: Collections impact vs. Non-Impact
- » Currently, 8 Issue Types Impacting DBA Payments
- » Currently in Testing (See sample dataset)
- » WCAAP Partnership: DBA coaching

SAMPLE DATA FYTD 2026 – RUN 10/15/2025 FOR ILLUSTRATION PURPOSES				
Issue Code	Issue Description	Count of Issue Description	% of Total	
B01	Billing Incorrect Modifier	888	5%	
B02	Billing Incorrect Grid Amt	14,378	83%	
B03	Billing Invalid CPT Code	674	4%	
B04	Billing Incorrect POS	1,050	6%	
B05	Payee EIN Not Equal WVA	N/A	N/A	
B06	Payee Name Not Equal WVA	110	1%	
B07	Wrong NPI: Provider NPI = WVA NPI	N/A	N/A	
B08	Inappropriate Age	134	age Number 12	
Total		17,234	100%	

## 3.a.iii. Supply Chain Efficiency Activities

- » COVID-19 Order Reductions
- » RSV and COVID-19 Ordering Caps
- » RSV Vaccine Transfers/ Expiring Dose Management
- » Data Sharing Effort Between DOH-WVA-WCAAP
- » WCAAP Partnership
  - » Provider Education
  - » Provider Coaching Project



### 3.b. Future of the Assessment Grid

### **Expected Changes to Assessment Grid Model in FY25-26**

- » Incorporation of Datasets: Shipment, Waste, Returns, Transfers, and Uptake
- » Updated Reserves Funding Factors
- » Revised Fund Source Split
- » Goal to Increase Vaccine Net Discount from 4% to 5-8%
- » Individual Grid Amounts for COVID-19 and Influenza Vaccines
- » Variable Discounts for Higher-Priced Vaccines

### **April 2026**

» FY2027 Assessment Grid Approved by Operations Committee



### 3.b. Weighted Average Grid Amount & Weighted Private Sector Price



Page Number 15

\*Under Revision: Increase from 4% to 5-8%

# Stay Connected

Sign up to stay informed: www.wavaccine.org/contact/

info@wavaccine.org

Ph 888-928-2224 | Fax 888-928-2242

**Mailing Address:** 

PO Box 94002 | Seattle, WA 98124-9402

www.wavaccine.org

